About
Antibody discovery & engineering
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Team (28)
Alexander Goergen
Vice President, Head of Business Development
Adagene
executive
Andy (Yiu Leung) Cheung
Independent Director
Adagene
board_member
Aurélien Marabelle, M.D., Ph.D.
Adagene
team_member
Axel Hoos, M.D., Ph.D.
Adagene
team_member
Chunfang (Vicky) Gu
Executive Director of Finance
Adagene
team_member
Cuong Do
Independent Director
Adagene
board_member
Clinical Trials (12)
View allTotal Trials
12
As Lead Sponsor
7
As Collaborator
5
Total Enrollment
1,067
By Phase
PHASE2: 1PHASE1/PHASE2: 6PHASE1: 5
By Status
RECRUITING: 5COMPLETED: 3ACTIVE_NOT_RECRUITING: 2UNKNOWN: 1TERMINATED: 1
Clinical Trials Pipeline12 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT06846268Collaborator
Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer
PHASE2Recruiting
20 participants
Started: Apr 14, 2025 · Completed: Dec 31, 2027
NCT05491083Collaborator
Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer
PHASE1/PHASE2Recruiting
51 participants
Started: Jun 12, 2023 · Completed: Dec 31, 2026
NCT05614258Lead Sponsor
Study of ADG206 in Subjects With Advanced/Metastatic Solid Tumors
PHASE1Recruiting
21 participants
Started: Feb 13, 2023 · Completed: Oct 31, 2025
NCT05405595Lead Sponsor
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
PHASE1/PHASE2Recruiting
152 participants
Started: Jun 15, 2022 · Completed: Apr 30, 2027
NCT05275777Collaborator
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
PHASE1/PHASE2Active, not recruiting
66 participants
Started: May 19, 2022 · Completed: Feb 28, 2030
Locations (1)
Headquarters
Suzhou, China
Map
Loading map...